Earnings Preview: Tarsus Pharmaceuticals

Tarsus Pharmaceuticals (NASDAQ:TARS) is gearing up to announce its quarterly earnings on Monday, 2026-02-23. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Tarsus Pharmaceuticals will report an earnings per share (EPS) of $-0.07.

Anticipation surrounds Tarsus Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Overview of Past Earnings

In the previous earnings release, the company beat EPS by $0.04, leading to a 4.62% drop in the share price the following trading session.

Here's a look at Tarsus Pharmaceuticals's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.34	-0.35	-0.63	-0.82
EPS Actual	-0.30	-0.48	-0.64	-0.60
Price Change %	-5.00	15.00	-6.00	3.00

Tracking Tarsus Pharmaceuticals's Stock Performance

Shares of Tarsus Pharmaceuticals were trading at $65.54 as of February 19. Over the last 52-week period, shares are up 42.61%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analyst Views on Tarsus Pharmaceuticals

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Tarsus Pharmaceuticals.

A total of analyst ratings have been received for Tarsus Pharmaceuticals, with the consensus rating being . The average one-year price target stands at $, suggesting a potential .

To track all earnings releases for Tarsus Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.